ZA200108636B - Tetracyclic azepinoindole compounds as 5-HT receptor ligands. - Google Patents

Info

Publication number

ZA200108636B

ZA200108636B ZA200108636A ZA200108636A ZA200108636B ZA 200108636 B ZA200108636 B ZA 200108636B ZA 200108636 A ZA200108636 A ZA 200108636A ZA 200108636 A ZA200108636 A ZA 200108636A ZA 200108636 B ZA200108636 B ZA 200108636B

Authority

ZA

South Africa

Prior art keywords

azepino

hexahydro

pyrrolo

disorder

alkyl

Prior art date

1999-04-23

Links

• Espacenet
• Global Dossier
• Discuss

• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title claims description 10
• 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 title claims description 9
• ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical class N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 title description 9
• 239000003446 ligand Substances 0.000 title description 6
• 150000001875 compounds Chemical class 0.000 claims description 236
• 125000000217 alkyl group Chemical group 0.000 claims description 212
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 181
• 125000003118 aryl group Chemical group 0.000 claims description 153
• 125000001072 heteroaryl group Chemical group 0.000 claims description 107
• 238000000034 method Methods 0.000 claims description 95
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 87
• -1 pyrrolidino, piperidino, morpholino Chemical group 0.000 claims description 72
• SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 61
• 229910052739 hydrogen Inorganic materials 0.000 claims description 53
• 239000001257 hydrogen Substances 0.000 claims description 50
• 125000003545 alkoxy group Chemical group 0.000 claims description 47
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 46
• 229910052799 carbon Inorganic materials 0.000 claims description 46
• 208000035475 disorder Diseases 0.000 claims description 46
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 45
• 201000010099 disease Diseases 0.000 claims description 41
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 39
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 39
• 239000000203 mixture Substances 0.000 claims description 39
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 38
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 38
• 150000003839 salts Chemical class 0.000 claims description 37
• 125000001589 carboacyl group Chemical group 0.000 claims description 35
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical group C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 35
• PMZDQRJGMBOQBF-UHFFFAOYSA-N 1H-quinolin-4-one Natural products C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 claims description 33
• FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 claims description 33
• 150000002431 hydrogen Chemical class 0.000 claims description 33
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
• 125000005843 halogen group Chemical group 0.000 claims description 28
• VSGPVHSTVTXREH-UHFFFAOYSA-N quinolin-4-one Chemical compound C1=CC=C[C]2C(=O)C=CN=C21 VSGPVHSTVTXREH-UHFFFAOYSA-N 0.000 claims description 28
• 125000004423 acyloxy group Chemical group 0.000 claims description 25
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 23
• 125000001424 substituent group Chemical group 0.000 claims description 23
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
• 241000124008 Mammalia Species 0.000 claims description 21
• 101100219283 Amycolatopsis orientalis cyp165C4 gene Proteins 0.000 claims description 20
• 208000028017 Psychotic disease Diseases 0.000 claims description 20
• 208000008589 Obesity Diseases 0.000 claims description 19
• 235000020824 obesity Nutrition 0.000 claims description 19
• 229920006395 saturated elastomer Polymers 0.000 claims description 19
• 208000019901 Anxiety disease Diseases 0.000 claims description 18
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 18
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
• 125000004432 carbon atom Chemical group C* 0.000 claims description 17
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 17
• 229910052757 nitrogen Inorganic materials 0.000 claims description 16
• 208000011580 syndromic disease Diseases 0.000 claims description 16
• 238000011282 treatment Methods 0.000 claims description 15
• 230000036506 anxiety Effects 0.000 claims description 14
• 210000003169 central nervous system Anatomy 0.000 claims description 14
• 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 13
• JLTRNSWADPSQBA-UHFFFAOYSA-N 4-azatricyclo[5.3.1.04,11]undeca-1(11),2,5,7,9-pentaene Chemical compound C1=CC2=CC=CC3=C2N1C=C3 JLTRNSWADPSQBA-UHFFFAOYSA-N 0.000 claims description 12
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 12
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 12
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 12
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
• 201000000980 schizophrenia Diseases 0.000 claims description 12
• 125000005505 thiomorpholino group Chemical group 0.000 claims description 12
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 11
• 125000002947 alkylene group Chemical group 0.000 claims description 11
• 125000005129 aryl carbonyl group Chemical group 0.000 claims description 11
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 11
• 208000019906 panic disease Diseases 0.000 claims description 11
• 208000019899 phobic disease Diseases 0.000 claims description 11
• 206010034912 Phobia Diseases 0.000 claims description 10
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 10
• 239000003814 drug Substances 0.000 claims description 10
• 230000002496 gastric effect Effects 0.000 claims description 10
• 210000000987 immune system Anatomy 0.000 claims description 10
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 10
• 125000006239 protecting group Chemical group 0.000 claims description 10
• XMIAFAKRAAMSGX-UHFFFAOYSA-N quinolin-5-amine Chemical compound C1=CC=C2C(N)=CC=CC2=N1 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 claims description 10
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 10
• 125000004104 aryloxy group Chemical group 0.000 claims description 9
• 210000000748 cardiovascular system Anatomy 0.000 claims description 9
• 210000005095 gastrointestinal system Anatomy 0.000 claims description 9
• 238000002560 therapeutic procedure Methods 0.000 claims description 9
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 8
• 101150065749 Churc1 gene Proteins 0.000 claims description 8
• 102100038239 Protein Churchill Human genes 0.000 claims description 8
• 125000004429 atom Chemical group 0.000 claims description 8
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
• 206010001497 Agitation Diseases 0.000 claims description 7
• 206010003805 Autism Diseases 0.000 claims description 7
• 208000020706 Autistic disease Diseases 0.000 claims description 7
• 208000020925 Bipolar disease Diseases 0.000 claims description 7
• 206010020772 Hypertension Diseases 0.000 claims description 7
• 208000019695 Migraine disease Diseases 0.000 claims description 7
• 208000019022 Mood disease Diseases 0.000 claims description 7
• 206010047700 Vomiting Diseases 0.000 claims description 7
• 238000013019 agitation Methods 0.000 claims description 7
• 230000003542 behavioural effect Effects 0.000 claims description 7
• 206010027599 migraine Diseases 0.000 claims description 7
• 125000000464 thioxo group Chemical group S=* 0.000 claims description 7
• 230000008673 vomiting Effects 0.000 claims description 7
• 208000000103 Anorexia Nervosa Diseases 0.000 claims description 6
• 206010002942 Apathy Diseases 0.000 claims description 6
• 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims description 6
• 206010006550 Bulimia nervosa Diseases 0.000 claims description 6
• 208000006561 Cluster Headache Diseases 0.000 claims description 6
• 208000027691 Conduct disease Diseases 0.000 claims description 6
• 208000024254 Delusional disease Diseases 0.000 claims description 6
• 206010012559 Developmental delay Diseases 0.000 claims description 6
• 208000001640 Fibromyalgia Diseases 0.000 claims description 6
• 206010019233 Headaches Diseases 0.000 claims description 6
• 208000016285 Movement disease Diseases 0.000 claims description 6
• 208000027520 Somatoform disease Diseases 0.000 claims description 6
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 6
• 206010048010 Withdrawal syndrome Diseases 0.000 claims description 6
• 208000012826 adjustment disease Diseases 0.000 claims description 6
• 238000002512 chemotherapy Methods 0.000 claims description 6
• 238000003745 diagnosis Methods 0.000 claims description 6
• 231100000869 headache Toxicity 0.000 claims description 6
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 6
• 230000005764 inhibitory process Effects 0.000 claims description 6
• 230000035987 intoxication Effects 0.000 claims description 6
• 231100000566 intoxication Toxicity 0.000 claims description 6
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
• 208000024196 oppositional defiant disease Diseases 0.000 claims description 6
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 6
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 6
• 208000020016 psychiatric disease Diseases 0.000 claims description 6
• 208000022610 schizoaffective disease Diseases 0.000 claims description 6
• 208000019116 sleep disease Diseases 0.000 claims description 6
• 208000020685 sleep-wake disease Diseases 0.000 claims description 6
• 208000016686 tic disease Diseases 0.000 claims description 6
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 5
• 208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
• 208000020358 Learning disease Diseases 0.000 claims description 5
• 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 5
• 208000020186 Schizophreniform disease Diseases 0.000 claims description 5
• 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 5
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 5
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 5
• 208000026725 cyclothymic disease Diseases 0.000 claims description 5
• 208000024732 dysthymic disease Diseases 0.000 claims description 5
• 208000029364 generalized anxiety disease Diseases 0.000 claims description 5
• 201000003723 learning disability Diseases 0.000 claims description 5
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 5
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 5
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
• 208000012672 seasonal affective disease Diseases 0.000 claims description 5
• 230000000697 serotonin reuptake Effects 0.000 claims description 5
• 230000002485 urinary effect Effects 0.000 claims description 5
• 241001061127 Thione Species 0.000 claims description 4
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• OELGUZFHKSNJKB-UHFFFAOYSA-N 13-bromo-5,9-diazatetracyclo[7.6.1.02,8.012,16]hexadeca-1(16),2(8),12,14-tetraene Chemical compound C1CNCCC2=C1C1=CC=C(Br)C3=C1N2CC3 OELGUZFHKSNJKB-UHFFFAOYSA-N 0.000 claims description 3
• OBHKVQCREXIFBE-UHFFFAOYSA-N 15-(2-methoxyphenoxy)-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraene Chemical compound COC1=CC=CC=C1OC(C1)CN2C(CCNCC3)=C3C3=C2C1=CC=C3 OBHKVQCREXIFBE-UHFFFAOYSA-N 0.000 claims description 3
• AATYYTKKUTVPIK-UHFFFAOYSA-N C1CNCCC2=C1N1CCOC3=CC=C(Br)C2=C31 Chemical compound C1CNCCC2=C1N1CCOC3=CC=C(Br)C2=C31 AATYYTKKUTVPIK-UHFFFAOYSA-N 0.000 claims description 3
• 239000004305 biphenyl Substances 0.000 claims description 3
• 150000001721 carbon Chemical group 0.000 claims description 3
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
• 125000001153 fluoro group Chemical group F* 0.000 claims description 3
• 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 3
• 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• MYASADAUXCJFGZ-UHFFFAOYSA-N C1CC=2C(C3=4)=CC=CC=4OC(C)CN3C=2CCN1C(=O)OCC1=CC=CC=C1 Chemical compound C1CC=2C(C3=4)=CC=CC=4OC(C)CN3C=2CCN1C(=O)OCC1=CC=CC=C1 MYASADAUXCJFGZ-UHFFFAOYSA-N 0.000 claims description 2
• PEXJSKNZTXLWFA-UHFFFAOYSA-N C1CC=2N(C3=4)CCOC=4C(F)=CC=C3C=2CCN1C(=O)OCC1=CC=CC=C1 Chemical compound C1CC=2N(C3=4)CCOC=4C(F)=CC=C3C=2CCN1C(=O)OCC1=CC=CC=C1 PEXJSKNZTXLWFA-UHFFFAOYSA-N 0.000 claims description 2
• 125000002837 carbocyclic group Chemical group 0.000 claims description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
• ZXLIDSBHMPQENO-UHFFFAOYSA-N pyrrolo[3,2,1-jk]carbazole Chemical compound C12=CC=CC=C2C2=CC=CC3=C2N1C=C3 ZXLIDSBHMPQENO-UHFFFAOYSA-N 0.000 claims description 2
• 239000000126 substance Substances 0.000 claims 12
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
• 210000000653 nervous system Anatomy 0.000 claims 3
• XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 claims 2
• 108090001069 Chymopapain Proteins 0.000 claims 2
• SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 1
• JFPHPIOXETYUOL-UHFFFAOYSA-N 10-[2-(2-bromophenoxy)ethoxy]-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraene Chemical compound BrC1=CC=CC=C1OCCOC1=CC=C2C3=C1C(CCNCC1)=C1N3CCC2 JFPHPIOXETYUOL-UHFFFAOYSA-N 0.000 claims 1
• GWMKVEISSFBMPP-UHFFFAOYSA-N 10-[2-(4-methylphenoxy)ethoxy]-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraene Chemical compound C1=CC(C)=CC=C1OCCOC1=CC=C2C3=C1C(CCNCC1)=C1N3CCC2 GWMKVEISSFBMPP-UHFFFAOYSA-N 0.000 claims 1
• TVGFBBLULNBBCT-UHFFFAOYSA-N 13-methoxy-5,9-diazatetracyclo[7.6.1.02,8.012,16]hexadeca-1(16),2(8),12,14-tetraene Chemical compound C1CNCCC2=C1C1=CC=C(OC)C3=C1N2CC3 TVGFBBLULNBBCT-UHFFFAOYSA-N 0.000 claims 1
• UMCBIAZBWQCXOW-UHFFFAOYSA-N 14-chloro-5,9-diazatetracyclo[7.6.1.02,8.012,16]hexadeca-1(15),2(8),12(16),13-tetraene Chemical compound C1CNCCC2=C1N1CCC3=C1C2=CC(Cl)=C3 UMCBIAZBWQCXOW-UHFFFAOYSA-N 0.000 claims 1
• HQVMTBXHTLIHLE-UHFFFAOYSA-N 15-(3-methoxyphenyl)sulfonyl-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraene Chemical compound COC1=CC=CC(S(=O)(=O)C2CN3C=4CCNCCC=4C=4C=CC=C(C3=4)C2)=C1 HQVMTBXHTLIHLE-UHFFFAOYSA-N 0.000 claims 1
• KLTNMSKUGFZQJV-UHFFFAOYSA-N 15-(trifluoromethyl)-5,9-diazatetracyclo[7.6.1.02,8.012,16]hexadeca-1(15),2(8),12(16),13-tetraene Chemical compound C1CNCCC2=C1N1CCC3=CC=C(C(F)(F)F)C2=C31 KLTNMSKUGFZQJV-UHFFFAOYSA-N 0.000 claims 1
• LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims 1
• 208000017194 Affective disease Diseases 0.000 claims 1
• JSYHUWRGUHDHSA-UHFFFAOYSA-N C1CNCCC(N2CCS3)=C1C1=C2C3=C(Cl)C(F)=C1 Chemical compound C1CNCCC(N2CCS3)=C1C1=C2C3=C(Cl)C(F)=C1 JSYHUWRGUHDHSA-UHFFFAOYSA-N 0.000 claims 1
• MDLMXNJOZVKVCF-UHFFFAOYSA-N C1CNCCC2=C1C1=C(F)C=C(F)C3=C1N2CCS3 Chemical compound C1CNCCC2=C1C1=C(F)C=C(F)C3=C1N2CCS3 MDLMXNJOZVKVCF-UHFFFAOYSA-N 0.000 claims 1
• SWOLCZSLIDLDRW-UHFFFAOYSA-N C1CNCCC2=C1C1=C3N2C(C)CC3=CC=C1 Chemical compound C1CNCCC2=C1C1=C3N2C(C)CC3=CC=C1 SWOLCZSLIDLDRW-UHFFFAOYSA-N 0.000 claims 1
• LYDXWRPZLPMEJU-UHFFFAOYSA-N C1CNCCC2=C1C1=CC=C(OC)C3=C1N2CCO3 Chemical compound C1CNCCC2=C1C1=CC=C(OC)C3=C1N2CCO3 LYDXWRPZLPMEJU-UHFFFAOYSA-N 0.000 claims 1
• IGTFHTXGJQYKJT-UHFFFAOYSA-N C1CNCCC2=C1N1CCC3=C1C2=CC(F)=C3 Chemical compound C1CNCCC2=C1N1CCC3=C1C2=CC(F)=C3 IGTFHTXGJQYKJT-UHFFFAOYSA-N 0.000 claims 1
• YQCFZKOBGYWHOR-UHFFFAOYSA-N C1CNCCC2=C1N1CCC3=C1C2=CC=C3 Chemical compound C1CNCCC2=C1N1CCC3=C1C2=CC=C3 YQCFZKOBGYWHOR-UHFFFAOYSA-N 0.000 claims 1
• JKDBGLPGAQLOAF-UHFFFAOYSA-N C1CNCCC2=C1N1CCSC3=C1C2=CC(OC)=C3 Chemical compound C1CNCCC2=C1N1CCSC3=C1C2=CC(OC)=C3 JKDBGLPGAQLOAF-UHFFFAOYSA-N 0.000 claims 1
• IVERCEIVYUXAIU-UHFFFAOYSA-N C1CNCCC2=C1N1CCSC3=C1C2=CC=C3 Chemical compound C1CNCCC2=C1N1CCSC3=C1C2=CC=C3 IVERCEIVYUXAIU-UHFFFAOYSA-N 0.000 claims 1
• RYIXMZKCFQKQMA-UHFFFAOYSA-N C=1C=C(C=23)OCCN3C=3CCNCCC=3C=2C=1OCC1=CC=CC=C1 Chemical compound C=1C=C(C=23)OCCN3C=3CCNCCC=3C=2C=1OCC1=CC=CC=C1 RYIXMZKCFQKQMA-UHFFFAOYSA-N 0.000 claims 1
• IKRCPYYFHZTYGY-UHFFFAOYSA-N C=1C=C(C=23)SCCN3C=3CCNCCC=3C=2C=1OCC1=CC=CC=C1 Chemical compound C=1C=C(C=23)SCCN3C=3CCNCCC=3C=2C=1OCC1=CC=CC=C1 IKRCPYYFHZTYGY-UHFFFAOYSA-N 0.000 claims 1
• 230000002526 effect on cardiovascular system Effects 0.000 claims 1
• 206010016256 fatigue Diseases 0.000 claims 1
• 238000000968 medical method and process Methods 0.000 claims 1
• KMVAXNRPZRSLSY-UHFFFAOYSA-N pha-57378 Chemical compound C1CNCCC2=C1N1CCOC3=C1C2=CC=C3 KMVAXNRPZRSLSY-UHFFFAOYSA-N 0.000 claims 1
• 238000002360 preparation method Methods 0.000 description 73
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 49
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
• 239000000243 solution Substances 0.000 description 25
• 125000000896 monocarboxylic acid group Chemical group 0.000 description 24
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
• 235000019439 ethyl acetate Nutrition 0.000 description 20
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
• 230000015572 biosynthetic process Effects 0.000 description 14
• 238000006243 chemical reaction Methods 0.000 description 14
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
• 239000000543 intermediate Substances 0.000 description 11
• 238000007363 ring formation reaction Methods 0.000 description 11
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 11
• 239000007788 liquid Substances 0.000 description 10
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
• 150000001412 amines Chemical class 0.000 description 9
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 9
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 9
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
• 230000000694 effects Effects 0.000 description 8
• 239000011976 maleic acid Substances 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 150000001298 alcohols Chemical class 0.000 description 7
• 239000012267 brine Substances 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 239000000284 extract Substances 0.000 description 7
• 150000002689 maleic acids Chemical class 0.000 description 7
• 239000003921 oil Substances 0.000 description 7
• 235000019198 oils Nutrition 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
• 238000004296 chiral HPLC Methods 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 150000002429 hydrazines Chemical class 0.000 description 6
• PSXRWZBTVAZNSF-UHFFFAOYSA-N hydron;quinoline;chloride Chemical compound Cl.N1=CC=CC2=CC=CC=C21 PSXRWZBTVAZNSF-UHFFFAOYSA-N 0.000 description 6
• 239000010410 layer Substances 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
• 238000002953 preparative HPLC Methods 0.000 description 6
• 150000003254 radicals Chemical class 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 238000004064 recycling Methods 0.000 description 6
• 238000010992 reflux Methods 0.000 description 6
• 238000000926 separation method Methods 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 238000000825 ultraviolet detection Methods 0.000 description 6
• 239000006185 dispersion Substances 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 238000010898 silica gel chromatography Methods 0.000 description 5
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• 150000001204 N-oxides Chemical class 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 239000012043 crude product Substances 0.000 description 4
• 239000006260 foam Substances 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
• ZFDIRQKJPRINOQ-HWKANZROSA-N Ethyl crotonate Chemical compound CCOC(=O)\C=C\C ZFDIRQKJPRINOQ-HWKANZROSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 235000019502 Orange oil Nutrition 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
• 229960000583 acetic acid Drugs 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 239000008346 aqueous phase Substances 0.000 description 3
• ORJQXZSDLARZBC-UHFFFAOYSA-N benzyl 4-oxoazepane-1-carboxylate Chemical compound C1CCC(=O)CCN1C(=O)OCC1=CC=CC=C1 ORJQXZSDLARZBC-UHFFFAOYSA-N 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 238000003818 flash chromatography Methods 0.000 description 3
• 239000012458 free base Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• RJTZUHVCZIGJMB-UHFFFAOYSA-N hydron;1h-indole;chloride Chemical compound Cl.C1=CC=C2NC=CC2=C1 RJTZUHVCZIGJMB-UHFFFAOYSA-N 0.000 description 3
• 150000002576 ketones Chemical group 0.000 description 3
• 239000010502 orange oil Substances 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 229910000027 potassium carbonate Inorganic materials 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 125000006413 ring segment Chemical group 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• ZFDIRQKJPRINOQ-UHFFFAOYSA-N transbutenic acid ethyl ester Natural products CCOC(=O)C=CC ZFDIRQKJPRINOQ-UHFFFAOYSA-N 0.000 description 3
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
• YMPFJXQFTCDJOB-UHFFFAOYSA-N 1-o-benzyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound C1CC(=O)C(C(=O)OCC)CCN1C(=O)OCC1=CC=CC=C1 YMPFJXQFTCDJOB-UHFFFAOYSA-N 0.000 description 2
• LICJMEFFNVODTH-UHFFFAOYSA-N 14-(4-bromo-2-methoxyphenyl)sulfonyl-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9(17),10,12-tetraene Chemical compound COC1=CC(Br)=CC=C1S(=O)(=O)C1C(C=CC=C2C=3CCNCCC=33)=C2N3CC1 LICJMEFFNVODTH-UHFFFAOYSA-N 0.000 description 2
• WJZBKRYEJCKWBN-UHFFFAOYSA-N 14-chloro-15-fluoro-5,9-diazatetracyclo[7.6.1.02,8.012,16]hexadeca-1(16),2(8),12,14-tetraene Chemical compound C1CNCCC2=C1N1CCC3=CC(Cl)=C(F)C2=C31 WJZBKRYEJCKWBN-UHFFFAOYSA-N 0.000 description 2
• SQVVSOXSSLKOAA-UHFFFAOYSA-N 15-(4-chlorophenoxy)-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraene Chemical compound C1=CC(Cl)=CC=C1OC(C1)CN2C(CCNCC3)=C3C3=C2C1=CC=C3 SQVVSOXSSLKOAA-UHFFFAOYSA-N 0.000 description 2
• GWSVGZZFGIFZCK-UHFFFAOYSA-N 15-phenylmethoxy-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-9,11,13(17)-triene Chemical compound C1N(C=23)C4CCNCCC4C3=CC=CC=2CC1OCC1=CC=CC=C1 GWSVGZZFGIFZCK-UHFFFAOYSA-N 0.000 description 2
• IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• OQMROOTVLOXIJH-UHFFFAOYSA-N 3,4-dihydro-2h-quinolin-1-amine Chemical class C1=CC=C2N(N)CCCC2=C1 OQMROOTVLOXIJH-UHFFFAOYSA-N 0.000 description 2
• VKWQSTIJYWQSAL-UHFFFAOYSA-N 6-methyl-3,4-dihydro-2h-1,4-benzoxazine Chemical compound O1CCNC2=CC(C)=CC=C21 VKWQSTIJYWQSAL-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000167854 Bourreria succulenta Species 0.000 description 2
• JCWNUOJFXKWFNY-UHFFFAOYSA-N C1=CC(Cl)=CC=C1NC(C1)CN2C(CCNCC3)=C3C3=C2C1=CC=C3 Chemical compound C1=CC(Cl)=CC=C1NC(C1)CN2C(CCNCC3)=C3C3=C2C1=CC=C3 JCWNUOJFXKWFNY-UHFFFAOYSA-N 0.000 description 2
• AHFYRUKAYHEKNY-UHFFFAOYSA-N C1CNCCC2=C1C1=CC=C(C)C3=C1N2CCS3 Chemical compound C1CNCCC2=C1C1=CC=C(C)C3=C1N2CCS3 AHFYRUKAYHEKNY-UHFFFAOYSA-N 0.000 description 2
• BICAUTJYZSPQBJ-UHFFFAOYSA-N C1CNCCC2=C1C1=CC=C(Cl)C3=C1N2CCS3 Chemical compound C1CNCCC2=C1C1=CC=C(Cl)C3=C1N2CCS3 BICAUTJYZSPQBJ-UHFFFAOYSA-N 0.000 description 2
• XLJBMYOBRRMZJX-UHFFFAOYSA-N C1CNCCC2=C1N1CCOC3=C1C2=CC(OC)=C3 Chemical compound C1CNCCC2=C1N1CCOC3=C1C2=CC(OC)=C3 XLJBMYOBRRMZJX-UHFFFAOYSA-N 0.000 description 2
• RXZKLSUSSYNSDR-UHFFFAOYSA-N C1CNCCC2=C1N1CCSC3=C1C2=CC(F)=C3 Chemical compound C1CNCCC2=C1N1CCSC3=C1C2=CC(F)=C3 RXZKLSUSSYNSDR-UHFFFAOYSA-N 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
• 229930091371 Fructose Natural products 0.000 description 2
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
• 239000005715 Fructose Substances 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• 238000006751 Mitsunobu reaction Methods 0.000 description 2
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
• AZARBVYBSPOIHB-UHFFFAOYSA-N N-(2-methoxyphenyl)-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraen-15-amine Chemical compound COC1=CC=CC=C1NC(C1)CN2C(CCNCC3)=C3C3=C2C1=CC=C3 AZARBVYBSPOIHB-UHFFFAOYSA-N 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
• CPVMNDJNIFRACQ-UHFFFAOYSA-N benzyl 4-(3,4-dihydro-2h-quinolin-1-ylimino)azepane-1-carboxylate Chemical compound C1CCC(=NN2C3=CC=CC=C3CCC2)CCN1C(=O)OCC1=CC=CC=C1 CPVMNDJNIFRACQ-UHFFFAOYSA-N 0.000 description 2
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 235000019693 cherries Nutrition 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical class CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 239000012362 glacial acetic acid Substances 0.000 description 2
• 150000007857 hydrazones Chemical class 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000012280 lithium aluminium hydride Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229920000137 polyphosphoric acid Polymers 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• GMBNHSBTDLMAAQ-UHFFFAOYSA-N (9-fluoro-2,4,5,6-tetrahydro-1h-azepino[4,5-b]indol-3-yl)-phenylmethanone Chemical compound C1CC=2C3=CC(F)=CC=C3NC=2CCN1C(=O)C1=CC=CC=C1 GMBNHSBTDLMAAQ-UHFFFAOYSA-N 0.000 description 1
• VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
• KNLIGWOOTSNNNJ-BTJKTKAUSA-N (Z)-but-2-enedioic acid 10,11-dichloro-14-oxa-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9(17),10,12-tetraene Chemical compound OC(=O)\C=C/C(O)=O.C1CNCCC2=C1N1CCOC3=C1C2=C(Cl)C(Cl)=C3 KNLIGWOOTSNNNJ-BTJKTKAUSA-N 0.000 description 1
• XARXITRLAJPTLX-BTJKTKAUSA-N (Z)-but-2-enedioic acid 11-chloro-14-oxa-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9(17),10,12-tetraene Chemical compound OC(=O)\C=C/C(O)=O.C1CNCCC2=C1N1CCOC3=C1C2=CC(Cl)=C3 XARXITRLAJPTLX-BTJKTKAUSA-N 0.000 description 1
• XZJIKCLKVIDSOQ-BTJKTKAUSA-N (Z)-but-2-enedioic acid 14-chloro-5,9-diazatetracyclo[7.6.1.02,8.012,16]hexadeca-1(15),2(8),12(16),13-tetraene Chemical compound OC(=O)\C=C/C(O)=O.C1CNCCC2=C1N1CCC3=C1C2=CC(Cl)=C3 XZJIKCLKVIDSOQ-BTJKTKAUSA-N 0.000 description 1
• PYVPMCZSTWELEJ-UHFFFAOYSA-N 1,2,3,4-tetramethyl-9h-carbazole Chemical compound C1=CC=C2C3=C(C)C(C)=C(C)C(C)=C3NC2=C1 PYVPMCZSTWELEJ-UHFFFAOYSA-N 0.000 description 1
• OGZPSADRULDABV-UHFFFAOYSA-N 1,2,8,9,10,11-hexahydro-7h-azepino[4,5-b][1,4]thiazino[2,3,4-hi]indole hydrochloride Chemical compound Cl.C1CNCCC2=C1N1CCSC3=C1C2=CC=C3 OGZPSADRULDABV-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
• 125000006039 1-hexenyl group Chemical group 0.000 description 1
• 125000006023 1-pentenyl group Chemical group 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
• HPLHOBPIYGRJMR-UHFFFAOYSA-N 10-benzoyl-4-methoxy-5,6,8,9,10,11,12,12a-octahydro-4h,7ah-azepino[4',5':4,5]pyrrolo[3,2,1-ij ]quinoline Chemical compound C1CC2C(C3=4)=CC=CC=4C(OC)CCN3C2CCN1C(=O)C1=CC=CC=C1 HPLHOBPIYGRJMR-UHFFFAOYSA-N 0.000 description 1
• HNOXTRWCRXOABB-UHFFFAOYSA-N 10-benzoyl-5,6,8,9,10,11,12,12a-octahydro-4h,7ah-azepino[4',5':4,5]pyrrolo [3,2,1-ij]quinolin-4-ol Chemical compound C1CC2C(C3=4)=CC=CC=4C(O)CCN3C2CCN1C(=O)C1=CC=CC=C1 HNOXTRWCRXOABB-UHFFFAOYSA-N 0.000 description 1
• LZOQAYFBOAOQJQ-UHFFFAOYSA-N 10-benzoyl-5,6,9,10,11,12-hexahydro-4h,8h-azepino [4',5':4,5]pyrrolo[3,2,1-ij]quinolin-4-one Chemical compound C1CC(N2CCC(=O)C=3C=CC=C4C2=3)=C4CCN1C(=O)C1=CC=CC=C1 LZOQAYFBOAOQJQ-UHFFFAOYSA-N 0.000 description 1
• CKGNLTZDLJXQOA-UHFFFAOYSA-N 11-methyl-14-oxa-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9(17),10,12-tetraene hydrochloride Chemical compound Cl.C1CNCCC2=C1N1CCOC3=C1C2=CC(C)=C3 CKGNLTZDLJXQOA-UHFFFAOYSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• PYFVEIDRTLBMHG-UHFFFAOYSA-N 2,3-dimethyl-1h-indole Chemical compound C1=CC=C2C(C)=C(C)NC2=C1 PYFVEIDRTLBMHG-UHFFFAOYSA-N 0.000 description 1
• CKIIJIDEWWXQEA-UHFFFAOYSA-N 2-(bromomethyl)-1,3-dioxolane Chemical compound BrCC1OCCO1 CKIIJIDEWWXQEA-UHFFFAOYSA-N 0.000 description 1
• QRWRJDVVXAXGBT-UHFFFAOYSA-N 2-Methylindoline Chemical compound C1=CC=C2NC(C)CC2=C1 QRWRJDVVXAXGBT-UHFFFAOYSA-N 0.000 description 1
• SWFNPENEBHAHEB-UHFFFAOYSA-N 2-amino-4-chlorophenol Chemical compound NC1=CC(Cl)=CC=C1O SWFNPENEBHAHEB-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• ICCYFVWQNFMENX-UHFFFAOYSA-N 2-chloro-6-nitrophenol Chemical compound OC1=C(Cl)C=CC=C1[N+]([O-])=O ICCYFVWQNFMENX-UHFFFAOYSA-N 0.000 description 1
• HIGRXCJEFUYRNW-UHFFFAOYSA-N 2-fluoro-6-nitrophenol Chemical compound OC1=C(F)C=CC=C1[N+]([O-])=O HIGRXCJEFUYRNW-UHFFFAOYSA-N 0.000 description 1
• 125000006040 2-hexenyl group Chemical group 0.000 description 1
• JZICUKPOZUKZLL-UHFFFAOYSA-N 2-methyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2NC(C)CCC2=C1 JZICUKPOZUKZLL-UHFFFAOYSA-N 0.000 description 1
• XZEDEVRSUANQEM-UHFFFAOYSA-N 2-nitro-4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O XZEDEVRSUANQEM-UHFFFAOYSA-N 0.000 description 1
• SYDNSSSQVSOXTN-UHFFFAOYSA-N 2-nitro-p-cresol Chemical compound CC1=CC=C(O)C([N+]([O-])=O)=C1 SYDNSSSQVSOXTN-UHFFFAOYSA-N 0.000 description 1
• 125000006024 2-pentenyl group Chemical group 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
• YBBLSBDJIKMXNQ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzothiazine Chemical class C1=CC=C2NCCSC2=C1 YBBLSBDJIKMXNQ-UHFFFAOYSA-N 0.000 description 1
• YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical class C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 description 1
• WWLKRYTUCGXZDL-UHFFFAOYSA-N 3,4-dihydro-2h-quinolin-1-amine;hydrochloride Chemical compound Cl.C1=CC=C2N(N)CCCC2=C1 WWLKRYTUCGXZDL-UHFFFAOYSA-N 0.000 description 1
• AJEHWOKVPSKSLG-UHFFFAOYSA-N 3,5-dichloro-2-nitrophenol Chemical compound OC1=CC(Cl)=CC(Cl)=C1[N+]([O-])=O AJEHWOKVPSKSLG-UHFFFAOYSA-N 0.000 description 1
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• GAWNBKUTBVLIPL-UHFFFAOYSA-N 3-fluoro-2-nitrophenol Chemical compound OC1=CC=CC(F)=C1[N+]([O-])=O GAWNBKUTBVLIPL-UHFFFAOYSA-N 0.000 description 1
• 125000006041 3-hexenyl group Chemical group 0.000 description 1
• BUZMGUAGCNSWQB-UHFFFAOYSA-N 3-methyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CC(C)CNC2=C1 BUZMGUAGCNSWQB-UHFFFAOYSA-N 0.000 description 1
• JHNLZOVBAQWGQU-UHFFFAOYSA-N 380814_sial Chemical compound CS(O)(=O)=O.O=P(=O)OP(=O)=O JHNLZOVBAQWGQU-UHFFFAOYSA-N 0.000 description 1
• CEFFUJIHZMPDID-UHFFFAOYSA-N 39224-65-2 Chemical compound OC1=CC(Cl)=C(Cl)C=C1[N+]([O-])=O CEFFUJIHZMPDID-UHFFFAOYSA-N 0.000 description 1
• KZODZOGGCQZLNF-UHFFFAOYSA-N 4,5-difluoro-2-nitrophenol Chemical compound OC1=CC(F)=C(F)C=C1[N+]([O-])=O KZODZOGGCQZLNF-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• MCCVRPMINWUWOS-UHFFFAOYSA-N 4-chloro-5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=C(Cl)C=C1[N+]([O-])=O MCCVRPMINWUWOS-UHFFFAOYSA-N 0.000 description 1
• HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
• 125000006042 4-hexenyl group Chemical group 0.000 description 1
• OXNZWCYNCDWCJA-UHFFFAOYSA-N 4-methyl-1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2C(C)CCNC2=C1 OXNZWCYNCDWCJA-UHFFFAOYSA-N 0.000 description 1
• GTFMIJNXNMDHAB-UHFFFAOYSA-N 4h-1,4-benzothiazin-3-one Chemical compound C1=CC=C2NC(=O)CSC2=C1 GTFMIJNXNMDHAB-UHFFFAOYSA-N 0.000 description 1
• TZBIRJIZHKDREJ-UHFFFAOYSA-N 5,9-diazatetracyclo[7.6.1.02,8.012,16]hexadeca-1(15),2(8),12(16),13-tetraen-7-yl(phenyl)methanone Chemical compound C1NCCC(C=2C=CC=C3CCN4C=23)=C4C1C(=O)C1=CC=CC=C1 TZBIRJIZHKDREJ-UHFFFAOYSA-N 0.000 description 1
• YMCIVAPEOZDEGH-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1h-indole Chemical compound ClC1=CC=C2NCCC2=C1 YMCIVAPEOZDEGH-UHFFFAOYSA-N 0.000 description 1
• MZDBQSFPAMTTIS-UHFFFAOYSA-N 5-chloro-2-nitrophenol Chemical compound OC1=CC(Cl)=CC=C1[N+]([O-])=O MZDBQSFPAMTTIS-UHFFFAOYSA-N 0.000 description 1
• QQVVAVSPGWOFKT-UHFFFAOYSA-N 5-chloro-4-fluoro-2-nitrophenol Chemical compound OC1=CC(Cl)=C(F)C=C1[N+]([O-])=O QQVVAVSPGWOFKT-UHFFFAOYSA-N 0.000 description 1
• QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 1
• 125000006043 5-hexenyl group Chemical group 0.000 description 1
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
• YYDYAQAVAHKFJO-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-indole Chemical compound COC1=CC=C2NCCC2=C1 YYDYAQAVAHKFJO-UHFFFAOYSA-N 0.000 description 1
• NQXUSSVLFOBRSE-UHFFFAOYSA-N 5-methyl-2-nitrophenol Chemical compound CC1=CC=C([N+]([O-])=O)C(O)=C1 NQXUSSVLFOBRSE-UHFFFAOYSA-N 0.000 description 1
• HSLNYVREDLDESE-UHFFFAOYSA-N 6-chloro-2,3-dihydro-1h-indole Chemical compound ClC1=CC=C2CCNC2=C1 HSLNYVREDLDESE-UHFFFAOYSA-N 0.000 description 1
• RVYDZMQIYQISAU-UHFFFAOYSA-N 6-chloro-5-fluoro-2,3-dihydro-1h-indole Chemical compound C1=C(Cl)C(F)=CC2=C1NCC2 RVYDZMQIYQISAU-UHFFFAOYSA-N 0.000 description 1
• NECDDBBJVCNJNS-UHFFFAOYSA-N 6-fluoro-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(F)=CC=C21 NECDDBBJVCNJNS-UHFFFAOYSA-N 0.000 description 1
• XOKMRXSMOHCNIX-UHFFFAOYSA-N 6-methyl-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(C)=CC=C21 XOKMRXSMOHCNIX-UHFFFAOYSA-N 0.000 description 1
• JSBZPNRRLJLZBE-UHFFFAOYSA-N 6-methyl-4h-1,4-benzoxazin-3-one Chemical compound O1CC(=O)NC2=CC(C)=CC=C21 JSBZPNRRLJLZBE-UHFFFAOYSA-N 0.000 description 1
• WDKNRIQDGSVRBO-UHFFFAOYSA-N 7-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound C1CCNC2=CC(OC)=CC=C21 WDKNRIQDGSVRBO-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• HYQKTUORRFFXLF-UHFFFAOYSA-N C1CC=2C(C=34)=C(Cl)C(F)=CC=3OCCN4C=2CCN1C(=O)OCC1=CC=CC=C1 Chemical compound C1CC=2C(C=34)=C(Cl)C(F)=CC=3OCCN4C=2CCN1C(=O)OCC1=CC=CC=C1 HYQKTUORRFFXLF-UHFFFAOYSA-N 0.000 description 1
• IRSNXBPLEXBWIB-UHFFFAOYSA-N C1CC=2C(C=34)=CC(F)=CC=3OCCN4C=2CCN1C(=O)OCC1=CC=CC=C1 Chemical compound C1CC=2C(C=34)=CC(F)=CC=3OCCN4C=2CCN1C(=O)OCC1=CC=CC=C1 IRSNXBPLEXBWIB-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• RMELKBBCMUHNOQ-UHFFFAOYSA-N Cl.C1CNCCC2=C1C1=C3N2C(C)CCC3=CC=C1 Chemical compound Cl.C1CNCCC2=C1C1=C3N2C(C)CCC3=CC=C1 RMELKBBCMUHNOQ-UHFFFAOYSA-N 0.000 description 1
• QXQRARKOBFUTQZ-UHFFFAOYSA-N Cl.C1CNCCC2=C1C1=C3N2CCCC3=CC=C1 Chemical compound Cl.C1CNCCC2=C1C1=C3N2CCCC3=CC=C1 QXQRARKOBFUTQZ-UHFFFAOYSA-N 0.000 description 1
• OPFZELUJXURJCA-UHFFFAOYSA-N Cl.C1CNCCC2=C1N1C(C)C(C)C3=C1C2=CC=C3 Chemical compound Cl.C1CNCCC2=C1N1C(C)C(C)C3=C1C2=CC=C3 OPFZELUJXURJCA-UHFFFAOYSA-N 0.000 description 1
• HBRFJTSZRSFJAW-UHFFFAOYSA-N Cl.C1CNCCC2=C1N1CCCC3=C1C2=CC(F)=C3 Chemical compound Cl.C1CNCCC2=C1N1CCCC3=C1C2=CC(F)=C3 HBRFJTSZRSFJAW-UHFFFAOYSA-N 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 239000002841 Lewis acid Substances 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 150000004008 N-nitroso compounds Chemical class 0.000 description 1
• IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• LDDPHVYIALRFNH-UHFFFAOYSA-N ac1l9iic Chemical compound O=C1C=CC2=CC=CC3=C2N1C=C3 LDDPHVYIALRFNH-UHFFFAOYSA-N 0.000 description 1
• 125000004036 acetal group Chemical group 0.000 description 1
• 238000007171 acid catalysis Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003420 antiserotonin agent Substances 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• KZLCCMBSJDXNDG-UHFFFAOYSA-N azepan-1-yl(phenyl)methanone Chemical compound C=1C=CC=CC=1C(=O)N1CCCCCC1 KZLCCMBSJDXNDG-UHFFFAOYSA-N 0.000 description 1
• ZMKPMNLSLLYATH-UHFFFAOYSA-N azepino[4,5-b]indole Chemical class C1=CN=CC=C2C3=CC=CC=C3N=C21 ZMKPMNLSLLYATH-UHFFFAOYSA-N 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• AJUJXTFALCYTJN-UHFFFAOYSA-N benzyl 14-methyl-1,5-diazatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9(17),10,12-tetraene-5-carboxylate Chemical compound C1CC=2C(C3=4)=CC=CC=4C(C)CCN3C=2CCN1C(=O)OCC1=CC=CC=C1 AJUJXTFALCYTJN-UHFFFAOYSA-N 0.000 description 1
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229910000085 borane Inorganic materials 0.000 description 1
• MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 239000006189 buccal tablet Substances 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 150000001669 calcium Chemical class 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000007958 cherry flavor Substances 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 239000012230 colorless oil Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 150000002118 epoxides Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 1
• ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 1
• YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 125000005908 glyceryl ester group Chemical group 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 238000007327 hydrogenolysis reaction Methods 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 150000002475 indoles Chemical class 0.000 description 1
• 150000002476 indolines Chemical class 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000006361 intramolecular Friedel-Crafts acylation reaction Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 150000007517 lewis acids Chemical class 0.000 description 1
• XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 150000002828 nitro derivatives Chemical class 0.000 description 1
• 238000007034 nitrosation reaction Methods 0.000 description 1
• RBXVOQPAMPBADW-UHFFFAOYSA-N nitrous acid;phenol Chemical class ON=O.OC1=CC=CC=C1 RBXVOQPAMPBADW-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000007968 orange flavor Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• DTWKAKKMDFGWLP-UHFFFAOYSA-N phenyl(2,4,5,6-tetrahydro-1h-azepino[4,5-b]indol-3-yl)methanone Chemical compound C1CC=2NC3=CC=CC=C3C=2CCN1C(=O)C1=CC=CC=C1 DTWKAKKMDFGWLP-UHFFFAOYSA-N 0.000 description 1
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 230000001624 sedative effect Effects 0.000 description 1
• 230000000862 serotonergic effect Effects 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000007892 solid unit dosage form Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 208000022170 stress incontinence Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000002936 tranquilizing effect Effects 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
• BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000009637 wintergreen oil Substances 0.000 description 1